Streetbeat News

Stock Prices

IPG

Interpublic Group of Companies (NYSE: IPG) reported Q2 2024 adjusted EPS of $0.61, beating the estimate of $0.59. However, sales of $2.327 billion missed the $2.329 billion estimate and decreased by 0.09% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 11:02 am

ODFL

Old Dominion Freight Line (NASDAQ: ODFL) reported Q2 2024 earnings per share (EPS) of $1.48, beating the analyst estimate of $1.46. However, sales of $1.498 billion slightly missed the estimate of $1.499 billion. EPS increased by 11.28% year-over-year, while sales grew by 6.02%.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 11:02 am

ALKS

Alkermes reported Q2 2024 adjusted EPS of $0.72, beating the estimate of $0.70. Sales were $399.131 million, surpassing the expected $393.348 million.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 11:02 am

WNC

Wabash has revised its FY24 revenue outlook downwards from $2.2B - $2.4B to $2.0B - $2.2B, and its EPS guidance from $2.00 - $2.50 to $1.50 - $1.60. The market estimate for revenue was $2.24B and for EPS was $2.06.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 10:58 am

ROP

Roper Technologies has provided its Q3 adjusted EPS guidance of $4.50-$4.54, which is below the estimated $4.63. For FY24, the company expects adjusted EPS to be in the range of $18.10-$18.25, compared to the estimated $18.19 and the prior range of $18.05-$18.25.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 10:57 am

LLY

NVO

PFE

RHHBY

Novo Nordisk's stock dipped 1.25% in pre-market trading despite the UK approving its weight loss drug, Wegovy, for reducing heart complications in overweight adults. Increased competition from Pfizer and Roche in the weight loss drug market also contributed to the decline.

Portfolio Pulse from Benzinga Neuro

July 24, 2024 | 10:57 am

ROP

Roper Technologies (NASDAQ:ROP) reported Q2 2024 adjusted EPS of $4.48, beating the estimate of $4.46. However, sales of $1.720 billion missed the $1.732 billion estimate. Sales increased by 12.34% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 10:56 am

THC

Tenet Healthcare has significantly raised its 2024 financial outlook, forecasting adjusted EPS of $10.41-$11.12, up from prior guidance of $8.37-$9.41 and consensus of $8.98. Revenue projections have also increased to $20.6B-$21B, compared to prior guidance of $20B-$20.4B and consensus of $20.493B. The outlook reflects the sale of several hospitals in South Carolina and California.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 10:55 am

EMLDU

Trading in EMLDU has been halted as of 6:55:00 a.m. ET pending news. Investors should stay tuned for further updates.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 10:55 am

EMLDW

Trading in EMLDW has been halted as of 6:55:00 a.m. ET pending news. Investors should stay tuned for further updates.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 10:55 am